Chugai Pharmaceutical experienced a significant drop in its stock value, falling 7.3%, marking the largest intraday decline since August 2025. Bloomberg posted on X that the decline followed the company's announcement to halt the development of an experimental drug aimed at treating specific diseases that lead to muscle weakness. The decision to discontinue the drug's development has raised concerns among investors, impacting the company's market performance.